Analytical challenges and technical limitations in assessing circulating MiRNAs
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: MiRNAs are emerging as promising biomarkers in cardiovascular diseases and may constitute a novel mechanism of intercellular communication. Accurate quantification of circulating miRNAs is essential. A variety of technological approaches and platforms have been developed with increased sensitivity and specificity for the detection and quantification of circulating miRNAs. In this review, we focus on the technical aspects and discuss the analytical challenges in profiling circulating miRNAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886 · cited 1×
“The mature miRNA is incorporated into the complex that recognises specific targets and induces posttranscriptional gene silencing by either translational repression or mRNA degradation through deadenylation (4, 5).”
BackgroundArroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
Processing of primary microRNAs by the Microprocessor complex
Denli, A. M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F., & Hannon, G. J. (2004) · Nature · doi:10.1038/nature03049 · Cited by 2,784 · cited 1×
“This imperfect miRNA-miRNA* duplex is then loaded into a multicomponent protein complex, the RNA-induced silencing complex (RISC) by associating with Argonaute proteins (Ago) (2, 3).”
BackgroundMicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
RNA sequencing: advances, challenges and opportunities
Ozsolak, F., & Milos, P. M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2934 · Cited by 2,135 · cited 1×
“High-throughput sequencing technologies offer a unique opportunity for detecting and profiling miRNA pools with unprecedented sensitivity (28) and can be applied to circulating miRNAs.”
BackgroundCharacterization of extracellular circulating microRNA
Turchinovich, A., Weiz, L., Langheinz, A., & Burwinkel, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr254 · Cited by 1,941
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 13×
“Due to the unique characteristics of miRNAs, designing a reverse transcription system to convert the miRNAs into cDNA requires (i) high specificity to ensure reverse transcription of mature miRNAs but not their precursors or genomic DNA, (ii) precision to discriminate among related miRNAs that differ by a single nucle…”
BackgroundMethodInfluentialExport of microRNAs and microRNA-protective protein by mammalian cells
Wang, K., Zhang, S., Weber, J., Baxter, D., & Galas, D. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq601 · Cited by 1,002
Next-generation DNA sequencing techniques
Ansorge, W. J. (2009) · New Biotechnology · doi:10.1016/j.nbt.2008.12.009 · Cited by 993
An optimized isolation and labeling platform for accurate microRNA expression profiling
SHINGARA, J., KEIGER, K., SHELTON, J., LAOSINCHAI-WOLF, W., POWERS, P., CONRAD, R., BROWN, D., & LABOURIER, E. (2005) · RNA · doi:10.1261/rna.2610405 · Cited by 260
Ach, R. A., Wang, H., & Curry, B. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-69 · Cited by 173
Consensus miRNA expression profiles derived from interplatform normalization of microarray data
Bargaje, R., Hariharan, M., Scaria, V., & Pillai, B. (2010) · RNA · doi:10.1261/rna.1688110 · Cited by 90
Cited by
MicroRNAs in cardiovascular disease: an introduction for clinicians
Romaine, S. P. R., Tomaszewski, M., Condorelli, G., & Samani, N. J. (2015) · Heart · doi:10.1136/heartjnl-2013-305402 · Cited by 476
Interplay between miRNAs and human diseases
Paul, P., Chakraborty, A., Sarkar, D., Langthasa, M., Rahman, M., Bari, M., Singha, R. S., Malakar, A. K., & Chakraborty, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25854 · Cited by 420
Circulating microRNAs as novel biomarkers for platelet activation.
Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., Kirkby, N. S., Crosby-Nwaobi, R., Prokopi, M., Drozdov, I., Langley, S. R., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300539 · Cited by 365
Self-citationThe Impact of Hemolysis on Cell-Free microRNA Biomarkers
Kirschner, M. B., Edelman, J. J. B., Kao, S. C.-H., Vallely, M. P., van Zandwijk, N., & Reid, G. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00094 · Cited by 352
Challenges in Using Circulating miRNAs as Cancer Biomarkers
Tiberio, P., Callari, M., Angeloni, V., Daidone, M. G., & Appierto, V. (2015) · BioMed Research International · doi:10.1155/2015/731479 · Cited by 271
Metadata
- Authors
- Mayr, M., & Zampetaki, A.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012
- Volume
- 108
- Issue
- 10
- Pages
- 592-598
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2091656909
- Cited by
- 125
- References
- 13
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.